Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVRRICANE: HIVIS DNA and MVA-CMDR Therapeutic Vaccines in HIV Youth
NCT04301154Phase 1Completed
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Start
- Feb 2022
- Primary completion
- Oct 2023
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DNA-HIVIS and MVA-CMDR in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Primary endpoints: Solicited and unsolicited serious adverse events at 1 year, Frequencies of CD4+ T cells that produce Tat/Rev transcription at 72 weeks and 1 more. Started Feb 2022; status: completed.
02
Drugs
DNA-HIVISMVA-CMDR
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04301154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301154.